用地高辛标记探针检测基因工程人β干扰素制品中的外源DNA

基因工程人β干扰素工程菌经发酵培养、纯化后获得纯的制品,采用斑点杂交技术,用非放射性地高辛标记超声裂解的全工程菌ＤＮＡ作为探针,检测基因工程人β干扰素纯品,结果显示：基因工程人β干扰素纯品中的外源ＤＮＡ含量小于１００ｐｇ／剂。     

虎耳草科落新妇族的研究

本文探讨了落新妇族Trib．Astilbeae的系统发育和地理分布。依据进化论、被子植物性状演化总趋势和外类群比较,确认了该族及其外类群Penthorum的重要性状(染色体基数,花粉纹饰,胎座式,心皮、雄蕊、花瓣和萼片数目,萼片脉型,叶型)的极性。采用徐克学(1989)最大同步法做了分支分析,推导出了该族的系统树图。系统树图表明：Rodgersia和Astilboides是一单系类群,而Astilbe为其姊妹群; Rodgersia较Astilbe进化,Astilboides则居二者之间;Penthorum是落新妇族的姊妹群,且与之有共同祖先。迄今为止,已知落新妇族共有24种和13变种(原变种除外)。分布于Takhtajan(1986)的东亚区、大西洋-北美区、伊朗-土兰区和马来西亚区。在东亚区,日本、朝鲜和中国(吉林-辽宁东部)有3属、17种和变种,占该族种与变种总数的45．9％,其中,含有不同演化水平的类群和该族原始种有Astilbe platyphylla,A.simplicifolia和Rodgersia podophylla,此地区是该族的起源中心、现代分布中心和分化中心。 横断山地区有2属、11种和变种,占29．7％,是另一现代分布中心。本族较进化的种Astilbe biternata、A. indica、A.khasiana和Rodgersia nepalensis等,均出现于远离起源中心地区。据此推断,本族植物的散布路线可能是从日本、朝鲜和中国(吉林-辽宁东部)向北通过东西伯利亚和白令陆桥,继而向东南进入北美东南部;向南经中国南部至菲律宾和爪哇,向西南越秦岭-大巴山山地、横断山,入喜马拉雅。落新妇属 Astilbe和鬼灯檠属Rodgersia均分布于亚洲大陆和日本岛屿,而日本于晚第三纪以来,即与亚洲大陆分离,故落新妇属和鬼灯檠属的形成,当在日本与亚洲大陆分离之前。据此推知,落新妇族的起源时间可能在早第三纪,或可追溯至晚白垩纪。     

中国寻螨属一新种记述(蜱螨亚纲:长须螨科)

寻螨属Zetzellia在中国曾报道了两种:苹果寻螨Z.mail(Ewing)和北京寻螨Z.beijing Wang and Xu1987.本文描述了寻螨属一新种,庐山寻螨Z.lushanensis sp.nov.模式标本保存于江西大学生物系.文内测量单位为μm。     

抑菌生的研究总结报告

本文报告一种由枯草杆菌制成的生态制剂,并命名为抑菌生(Subtilobiogen)。该制剂对创、烧伤感染有治疗作用。经过安全试验、急性毒性试验、Ames试验和微核试验证明,该制剂是一种无害、无毒和有致突变作用的活菌制剂。抑菌生有膏剂、乳剂及粉剂3种剂型。抑菌生在试管和体内对金黄色葡萄球菌、绿脓杆菌和大肠杆菌均具有抑菌作用。临床观察证明,将抑菌生喷洒在创面上,对浅Ⅱ°度、深Ⅱ°度及混合型烧伤感染均具有明显疗效。实验组(181例)与对照组(174例)相比较,在统计学上具有显著性差异。抑菌生的作用机制,经过初步试验证明,与营养争夺和占位性保护有关,因为枯草杆菌的生长速度超过金黄色葡萄球菌、绿脓杆菌和大肠杆菌的生长速度。     

Dye standards, Part II.5: Pararosaniline (CI 42500)

The names and affiliations of the SRMTS members are cited in Part I: terminology and general principles,Histochem. J. (1992)24, 217–19.     

Cis-trans isomerization of an angiotensin I-converting enzyme inhibitor. An enzyme kinetic and nuclear magnetic resonance study

The angiotensin I-converting enzyme (peptidyl-dipeptide hydrolase, EC 3.4.15.1) inhibitor, ramiprilat (2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-Ala]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid), is shown to exist in tow conformational isomers, cis and trans, which interconvert around the amide bond. The two conformers were separated by reversed-phase high-performance liquid chromatography. The conformers were identified by nuclear Overhauser effect measurements. From line shape analysis the isomerization rate constants were determined to be kcis----trans = 15 s-1 and ktrans----cis = 5 s-1 at 368 K in [2H]phosphate buffer (p2H 7.5). By enzyme kinetic studies using 3-(2-furylacryloyl)-L-Phe-Gly-Gly as substrate, the trans conformer was found to be the most potent enzyme inhibitor, whereas the cis conformer had a very low inhibitory effect. A new inhibition mechanism is presented for this type of slow, tight-binding inhibitors that contain an amide bond. This mechanism involves an equilibrium between the two conformers and the enzyme-bound inhibitor complex.     

Immunotherapy for remission maintenance in acute myeloblastic leukemia

Summary Forty-eight patients with acute myeloblastic leukemia in remission were treated with immunotherapy in addition to remission-maintenance chemotherapy. The first 16 patients were treated with weekly BCG and a leukemia cell vaccine (group 1). The next 32 patients were randomly allocated to receive BCG and a leukemia cell vaccine given once monthly (group 2) or BCG given monthly with no leukemia cell vaccine (group 3). There was no significant difference in remission duration or survival between the randomly allocated groups (2 and 3).Comparisons with group 1 are limited by the non-random allocation to this group, but selection bias was unlikely and clinical features were similar in the three patient groups. No significant difference in remission duration or survival was seen amongst the three groups studied. There was no advantage in the addition of leukemia cell vaccine (groups 1 and 2) to BCG alone (group 3) and no advantage to weekly (group 1) versus monthly immunotherapy (groups 2 and 3). Only 7 of the 48 patients achieved a second remission, and 4 of these were short-term partial remissions.The following are contributing members of the Toronto Leukemia Study Group: Doctor's Hospital, Harvey Silver MD; Humber Memorial Hospital, Alan Seidenfeld MD; Mississauga Hospital, Michael King MD; Mount Sinai Hospital, Dominic Amato MD; Northwestern Hospital, Wilhelm Kwant MD; Oshawa General Hospital, Hak Chiu MD; St Michael's Hospital, Bernadette Garvey MD, Kenneth Butler MD; St Joseph's Hospital, H. James Watt MD, Murray Davidson MD; Toronto General Hospital, Gerald Scott MD, William Francombe MD, Kenneth Shumak MD; John Crookston MD, PhD; Toronto Western Hospital, James G. Watt MD, David Sutton MD; Michael Baker MD; Domenic Pantalony MD; Wellesley Hospital, Dale Dotten MD; Women's College Hospital, George Kutas MD; York Finch Hospital, Sam Berger MD